New weekly shot aims to reverse fatty liver damage
NCT ID NCT07145151
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study tests a new drug called UBT251, given as a weekly injection, for people with MASH (a serious fatty liver disease with scarring). 156 adults will be randomly assigned to receive one of three doses of UBT251 or a placebo for 48 weeks. The main goal is to see if the drug can resolve MASH without worsening liver fibrosis.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
UBT251 (a weekly injection)
What this could lead to
If successful, this could point toward a new treatment for MASH that reduces liver scarring and inflammation.
What could go wrong
This is an early Phase 2 trial with only 156 people. The drug may not work better than placebo, and side effects are still being studied.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH) are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Beijing Tsinghua ChangGung Hospital
RECRUITINGBeijing, Beijing Municipality, 100044, China
Contact Phone: •••-•••-•••• Email: •••••@•••••